All patients
corticosteroids: no corticosteroids: yes
tocilizumab in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
0.96 [0.71 ; 1.30 ] COVACTA (Rosas), 2020, NCT04412772 (ARCHITECTS), 0, Rosas (REMDACTA), 2021 3 0% 1,099 moderate not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
EMPACTA, 2020 1.13 [0.54; 2.40]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
1.05 [0.80 ; 1.36 ] BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, EMPACTA, 2020, NCT04412772 (ARCHITECTS), 0, Rosas (REMDACTA), 2021 5 0% 1,732 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
1.03 [0.77 ; 1.38 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021 2 0% 1,092 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
EMPACTA, 2020 0.55 [0.33; 0.92]
0.76 [0.38 ; 1.51 ] BACC Bay Tocilizumab Trial, 2020, EMPACTA, 2020 2 65% 242 moderate not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
EMPACTA, 2020 1.15 [0.90; 1.47]
1.12 [0.95 ; 1.33 ] BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, EMPACTA, 2020 3 0% 680 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
1.19 [0.81 ; 1.75 ] COVACTA (Rosas), 2020 1 0% 438 NA not evaluable clinical improvement (time to event analysis only)detailed results EMPACTA, 2020 1.15 [0.90; 1.47]
1.15 [0.90 ; 1.47 ] EMPACTA, 2020 1 0% NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
EMPACTA, 2020 0.56 [0.32; 0.97]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
0.81 [0.57 ; 1.16 ] BACC Bay Tocilizumab Trial, 2020, EMPACTA, 2020, Rosas (REMDACTA), 2021 3 33% 891 moderate not evaluable hospital dischargedetailed results EMPACTA, 2020 1.16 [0.90; 1.49]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.05 [0.88 ; 1.25 ] EMPACTA, 2020, Rosas (REMDACTA), 2021 2 13% 649 moderate not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
0.67 [0.39 ; 1.14 ] COVACTA (Rosas), 2020 1 0% 273 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
0.48 [0.25 ; 0.94 ] COVACTA (Rosas), 2020 1 0% 191 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
0.86 [0.67 ; 1.11 ] BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021 3 0% 1,322 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
1.11 [0.74 ; 1.67 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021 2 41% 1,080 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-23 13:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 395
- roots T: 290
